hepatitis B

Latest Headlines

Latest Headlines

Diabetics under 60 should get hep B vaccine

In addition to its recommendations about the HPV shot for boys, the CDC's Advisory Committee on Immunization Practices said diabetics under the age of 60 should get the hepatitis B vaccine. Experts

Inovio, VGX ink hep B and C vaccine deal

Blue Bell, PA-based Inovio Pharmaceuticals and VGX International will collaborate on the development of Inovio's synthetic vaccines for hepatitis B and hepatitis C. Financial details of the deal were

HepB vax Heplisav posts positive Ph3 data

Dynavax ($DVAX), which is based in Berkeley, CA, released a new round of Phase III data on its hepatitis B vaccine, Heplisav. The data focused on specific hypo-responsive groups--males, smokers and

Dynavax's Heplisav performs well, but shows product inconsistency

Despite generally positive late-stage results for its experimental hepatitis B vaccine, Heplisav, Dynavax's stock price suffered after test lots showed product inconsistencies and a loss in Q2

The CIA, bin Laden and the future of vaccine programs

As U.S. intelligence zeroed in on Osama bin Laden's location in Abbottabad, Pakistan, the CIA found a useful front to obtain his family DNA: a hepatitis B vaccine program. It's unknown if the CIA

Merck, Sanofi start Ph3 pediatric vax trial

Investigators have started a Phase III study in the U.S. of a hexavalent pediatric vaccine created by Merck and Sanofi Pasteur. The vaccine is designed to protect against diphtheria, tetanus,

Vaccines may prevent certain childhood cancers

A study published in the Journal of Pediatrics finds that some vaccines may lower the risk of certain childhood cancers, including leukemia. Specifically, children who received the hepatitis B shot

Gates: Disease prevention most beneficial in developing countries

In a move to continue supporting vaccination efforts abroad, Bill Gates donated $50 million to fund a myriad of vaccinations in the Middle East. And this time, he had matched support from Sheik

Pharmasset touts promising PhIIa hep C data

Pharmasset (NASDAQ: VRUS) touted a promising batch of mid-stage data for its hepatitis C therapy and promised to swiftly pivot into a Phase IIb trial that could provide longer-term feedback on

Vaccination campaigns beat back viral hepatitis

The most serious types of viral hepatitis show signs of a steady retreat, beaten back by years of persistent vaccination campaigns in the U.S. Experts at the CDC say that there's been a decrease of